# BPC-157 legal status, FDA 503A category, and compounding access > BPC-157 legal status: not an FDA-approved drug, placed in FDA 503A Category 2 (significant safety risks) effective September 29, 2023, and individually named on the July 2026 PCAC agenda under active review. The current FDA position, read present-tense and cited — plus the scheduled July 2026 evaluation that has BPC-157 named by FDA as a substance under active review. General information, not medical or legal advice. ## Access is under active FDA review — and may expand in 2026 The headline on BPC-157 access right now is momentum: it is under active FDA review and may expand in 2026. BPC-157 — listed by FDA as the entries "BPC-157 (free base)" and "BPC-157 acetate" — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [13]. The same agenda also lists KPV, TB-500, and MOTs-C [13]. That is a scheduled evaluation and discussion only. A PCAC discussion is advisory; it is not a listing decision, not a reclassification, and not a change in BPC-157's current status [13]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC, and being discussed by the committee is a step in evaluation, not an outcome [11]. The forward-leaning fact here is genuine — BPC-157 is on the calendar, by name — and so is the limit on what it means. ## The current fact: not FDA-approved, and in 503A Category 2 BPC-157 is not an FDA-approved drug. FDA placed it in 503A "Category 2" — bulk substances FDA identified as raising significant safety risks — effective with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A [12]. FDA's stated concerns for BPC-157 include potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [12]. Under FDA's interim policy, Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [11]. In plain terms: as a Category 2 substance, BPC-157 is not within FDA's enforcement-discretion policy for 503A compounding, and it is not eligible for routine 503A compounding while that status stands [11][12]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 is neither [11]. ## What "Category 2" means under the 503A framework Drug compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [11]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet listed are evaluated by FDA through a public nomination process with input from PCAC [11]. FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks; not covered) [11]. On January 7, 2025, FDA finalized a revised interim policy under which it does not place substances nominated on or after that date into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated [11]. ## How legally compounded peptide access works In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [14]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [14]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [14]. The compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [14]. Applied to BPC-157: the pathway itself is general and lawful, but the ingredient-eligibility caveat is the operative point, because BPC-157 currently sits in Category 2 [12]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. ## Other status notes, and what is not yet confirmed Beyond the FDA compounding question, BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency under its S0 non-approved-substances category — a relevant point for athletes [6]. And because the peptide is not an approved drug and is widely distributed through non-regulated channels, product identity, purity, and dose are unverified outside formal studies [6]. One caution on rumor. Several commercial and clinic sources have circulated reports of an early-2026 reclassification moving peptides back toward Category 1, and of specific 2026 dates on which BPC-157 was supposedly "removed" from Category 2. None of these could be confirmed from an authoritative FDA source, and the most candid of those sources concedes the formal reclassification is still pending — so this bulletin does not treat any reclassification or removal as having occurred [11]. Notably, FDA's own PCAC agenda still lists BPC-157 as a candidate "being considered for inclusion on the 503A Bulks List" for July 2026, which is consistent with its evaluation being ongoing rather than resolved [13]. ## Access and regulatory questions ### Is BPC-157 legal? BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances identified as raising significant safety risks — effective September 29, 2023 [12]. As a Category 2 substance it is not within FDA's enforcement-discretion policy for 503A compounding [11]. It is also prohibited in sport at all times by WADA [6]. This is general regulatory information, not legal advice. ### Can you get BPC-157 from a compounding pharmacy? A 503A compounding pharmacy may use a bulk substance only if it is eligible under the 503A rules, and BPC-157 currently sits in Category 2, which is not within FDA's enforcement-discretion policy for routine 503A compounding [11][12]. The lawful pathway in general is licensed-prescriber evaluation, a valid patient-specific prescription, then a 503A pharmacy or 503B outsourcing facility — but that ingredient-eligibility caveat is the operative limit while the Category 2 status stands [14]. ### What is the FDA 503A status of BPC-157? FDA placed BPC-157 (entries "BPC-157 (free base)" and "BPC-157 acetate") in 503A Category 2, effective with its September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes and peptide impurity and characterization complexity [12]. It is individually named on the July 23-24, 2026 PCAC agenda as a substance "being considered for inclusion on the 503A Bulks List" — a scheduled discussion, not a decision [13]. --- A constructivist research bulletin on the BPC-157 record — each finding plated to its study, the human-data gap and the FDA 503A status posted before anything else, and no clinic behind the board nor anything here dispensed or sold.